Prognostic Value of Biomarkers in RCC

Video

Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Related Content
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 15th 2025
Article
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 15th 2025
Podcast
Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Ariana Pelosci
August 15th 2025
Article
Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
August 15th 2025
Podcast
Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
August 15th 2025
Article
A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
August 15th 2025
Article